Investing.com - Citius Pharma (NASDAQ: CTXR) reported third quarter EPS of $-0.060, in line with the analyst estimate of $-0.060. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Citius Pharma's stock price closed at $0.920. It is down -18.580% in the last 3 months and down -27.320% in the last 12 months.
Citius Pharma saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Citius Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Citius Pharma's Financial Health score is "good performance".
Check out Citius Pharma's recent earnings performance, and Citius Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar